FDA Orders Juul Products to Be Removed from Retailers

Jul.01.2022
FDA Orders Juul Products to Be Removed from Retailers
FDA tried to order retailers to remove Juul products but a federal appeals court suspended the order, citing contrasting arguments.

If the U.S. Food and Drug Administration (FDA) has its way, one of the largest electronic cigarette retailers in the country may be forced out of business. Last Thursday, the FDA began sending letters to retailers ordering them to remove all Juul products from their shelves. The following day, a federal appeals court temporarily suspended the FDA's order, allowing Juul to continue selling its products while the court hears arguments from both sides.

 

The FDA is alleging that Juul has not provided "sufficient evidence regarding the toxicological characteristics of their products to demonstrate that their marketing is appropriate for protecting public health." In response, Juul released a statement calling the FDA's ban "arbitrary and capricious.

 

Is Juuling on the way out?

 

This week, health reporter for Time, Jamie Ducharme argued that the ban on Juul may not be the public health victory that people have imagined, and pointed out that "adult smokers also use Juul for smoking cessation - last week's decision was not a victory for them.

 

Tim Andrews from the US Tax Reform Organization also wrote in the Washington Post that taking Juul products off the market "will cut off a proven method that helps millions of smokers quit, leading to more smoking and more deaths." As evidence, Andrews cited comments "consistently finding e-cigarettes two to six times more effective than other cessation devices" and a study by Georgetown University Medical Center, which estimated that e-cigarettes could save the lives of up to 6.6 million Americans who would live at least 10 years longer.

 

Jonathan Foulds, a professor of public health sciences at Pennsylvania State University, agrees with this sentiment, stating on Twitter that "banning smoking from these life-saving exits because of 'potentially harmful chemicals' that may exude from some pods is a bit like locking the fire escape door because the steps might be slippery.

 

What's worse, Zule or cigars?

 

In his article for the Washington Post, Tim Andrews cited a "meta-analysis" of scientific research on e-cigarettes, commissioned by the UK government and "replicated by external medical institutions," which concluded that e-cigarettes are "95% safer than combustible tobacco." Bloomberg reporters Fiona Rutherford and Robert Langreth acknowledged that "some evidence suggests that e-cigarettes are a safer option than smoking," but claim that "there is not enough long-term data to draw a definitive conclusion." It is worth noting that Michael Bloomberg is a major funder of the campaign to ban flavored e-cigarette products.

 

From April 2019 to February 2020, the US experienced an outbreak of lung injuries related to the use of electronic cigarettes or vaping products, known as EVALI, resulting in 2,807 hospitalizations and 68 deaths. Of note, 82% of hospitalized patients reported using marijuana while only 14% reported nicotine use alone. The Centers for Disease Control and Prevention also found that many of the deaths or hospitalizations were linked to the use of unregulated black-market THC products in their vaping devices. In comparison, smoking is estimated to cause 480,000 deaths per year in the US.

 

However, electronic cigarettes may not be the healthy alternative that some supporters claim. The Johns Hopkins School of Medicine notes that electronic cigarettes have not been approved by the Food and Drug Administration as a smoking cessation device, and "recent research has found that the majority of people who intended to use electronic cigarettes to quit nicotine habit ended up continuing to use both traditional cigarettes and e-cigarettes.

 

Just think about the children!

 

In 2018, 30% of American high school students "reported having tried nicotine at least once in the past year," according to a cover story by Jamie Ducharme in TIME magazine in 2019. This is the largest increase in substance use in at least 44 years. The 2018 report by the National Academy of Sciences also showed that children who use e-cigarettes are more likely to try traditional cigarettes. Although the FDA's decision did not specifically address the relationship between Juul and youth e-cigarette use, as reported by the New York Times, "public health experts and legislators continue to express concern about the addition of nicotine to some e-cigarettes that remain on the market, including brands like PuffBar that offer fruit flavors that are attractive to young people.

 

However, the theory still remains debatable. Writing for a conservative independent women's forum, Lindsey Stroud argues that Juul does not encourage children to smoke. According to a public opinion survey, she wrote, "From 2019 to 2021, the usage of Juul products among 12th-grade students decreased by 46.9% in the past 30 days. Additionally, in 10th-grade students, the number of people using JUUL decreased by 75.3% during that time." The editorial board of The New York Daily News agreed, writing that Juul "has largely lost favor with teenage consumers" in recent years. However, all of this may just be a passing trend, like water vapor evaporating in the wind.

 

Source: The Week

 

This article contains excerpts or reprints of third-party information. The copyright of the reproduced information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24